Compare Nerdwallet Inc (NRDS) vs Natera Inc. Common Stock (NTRA) Price & Performance

NRDS trades at $9.55, down 2.75% today, but maintains strong fundamentals with a P/E of 10.71 and P/S of 0.8, indicating potential undervaluation. The company has shown consistent revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Technical indicators show a bullish trend with strong moving average signals, though RSI levels suggest potential overbought conditions.

The outlook for NRDS remains positive with analyst consensus at 66.7% buy ratings and projected 27.9% upside potential. Strong profitability metrics include 93.5% gross margins and 18.16% ROE. Key risks include competitive pressures in financial guidance markets and reliance on organic search traffic. The company's improving cash flow from operations ($132M in 2025) supports continued growth initiatives in personal loans and deposit accounts.

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.